TG Therapeutics and Ildong Pharmaceutical have signed a licensing deal to develop and commercialize an oncology candidate, Ublituximab, in South Korea and Southeast Asia. Under the contract, Ildong gains Ublituximab development rights in ...
Tags: TG, Ildong Pharmaceutical, Ublituximab